Company: PAII-WT
Filing Date: 2025-06-27
Form Type: S-1
Source: 0001213900-25-059054
Chunk: 128

Company: Pyrophyte Acquisition Corp. II
Filing Date: 2025-06-27
Form: S-1
Chunk 128
---
 and may result in findings, orders or other determinations adverse to members of our management team or board of directors or our advisors, or otherwise negatively affect our reputation, which may impede our ability to complete an initial business combination and may have an adverse effect on the price of our securities. Members of our management team and board of directors, our advisors and affiliated companies may have been, and may in the future be, involved in civil disputes or governmental investigations unrelated to our business. Members of our management team and board of directors, our advisors and affiliated companies have been (and intend to continue to be) involved in a wide variety of businesses. Such involvement has, and may lead to, media coverage and public awareness. may continue to lead to, media coverage and public awareness. As a result, members of our management team and board of directors, our advisors and affiliated companies have been, and may in the future be, involved in civil disputes or governmental investigations unrelated to our company. Any such claims or investigations may be detrimental to our reputation and could negatively affect our ability to identify and complete an initial business combination and may have an adverse effect on the price of our securities.

| 89 |

| Risk factors |

Our letter agreement with our sponsor, officers and directors may be amended without shareholder approval. Our letter agreement with our sponsor, officers and directors contain provisions relating to transfer restrictions of our founder shares and private placement warrants, indemnification of the trust account, waiver of redemption rights and participation in liquidating distributions from the trust account. The letter agreement may be amended without shareholder approval (although releasing the parties from the restriction not to transfer the founder shares for 180 days following the date of this prospectus will require the prior written consent of the underwriters). While we do not expect our board to approve any amendment to the letter agreement prior to our initial business combination, it may be possible that our board, in exercising its business judgment and subject to its fiduciary duties, chooses to approve one or more amendments to the letter agreement. Any such amendments to the letter agreement would not require approval from our shareholders and may have an adverse effect on the value of an investment in our securities. Risks Relating to our Securities You will not have any rights or interests in funds from the trust account, except under certain limited circumstances. Therefore, to liquidate your investment, you may be forced to sell your public shares or warrants, potentially at a loss. Our public shareholders will be entitled to receive funds from the trust account only upon the earliest to occur of: